Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.
Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D. Eijkelkamp WB, et al. Among authors: remuzzi g. J Hypertens. 2007 Apr;25(4):871-6. doi: 10.1097/HJH.0b013e328014953c. J Hypertens. 2007. PMID: 17351381
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Mix TC, et al. Among authors: remuzzi g. Am Heart J. 2005 Mar;149(3):408-13. doi: 10.1016/j.ahj.2004.09.047. Am Heart J. 2005. PMID: 15864229
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A. Haller H, et al. Among authors: remuzzi g. J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6. J Hypertens. 2006. PMID: 16508590 Clinical Trial.
Renoprotective effects of renin-angiotensin-system inhibitors.
de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME. de Zeeuw D, et al. Among authors: remuzzi g. Lancet. 2006 Mar 18;367(9514):899-900; author reply 900-2. doi: 10.1016/S0140-6736(06)68374-8. Lancet. 2006. PMID: 16546533 No abstract available.
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Eijkelkamp WB, et al. Among authors: remuzzi g. J Am Soc Nephrol. 2007 May;18(5):1540-6. doi: 10.1681/ASN.2006050445. Epub 2007 Apr 4. J Am Soc Nephrol. 2007. PMID: 17409317 Clinical Trial.
1,535 results